Setmelanotide
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Rhythm · Phase 3 · Completed · Enrollment 19
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Run-in Period: Setmelanotide 2 mg QD | Bardet-Biedl Syndrome; POMC Deficiency | 2 mg | 1 | n/r | n/r |
| Run-in Period: Setmelanotide 2.5 mg QD | Bardet-Biedl Syndrome; POMC Deficiency | 2.5 mg | 1 | n/r | n/r |
| Run-in Period: Setmelanotide 3 mg QD | Bardet-Biedl Syndrome; POMC Deficiency | 3 mg | 1 | n/r | n/r |
| DB Period: Setmelanotide 20 mg QW | Bardet-Biedl Syndrome; POMC Deficiency | 20 mg | 1 | n/r | n/r |
| DB Period: Setmelanotide 25 mg QW | Bardet-Biedl Syndrome; POMC Deficiency | 25 mg | 1 | n/r | n/r |
| DB Period: Setmelanotide 3 mg QD | Bardet-Biedl Syndrome; POMC Deficiency | 3 mg | 1 | n/r | n/r |
| DB Period: Setmelanotide 30 mg QW | Bardet-Biedl Syndrome; POMC Deficiency | 30 mg | 1 | n/r | n/r |
| OL Period: Setmelanotide 20 mg QW | Bardet-Biedl Syndrome; POMC Deficiency | 20 mg | 1 | n/r | n/r |
| OL Period: Setmelanotide 25 mg QW | Bardet-Biedl Syndrome; POMC Deficiency | 25 mg | 1 | n/r | n/r |
| OL Period: Setmelanotide 30 mg QW | Bardet-Biedl Syndrome; POMC Deficiency | 30 mg | 1 | n/r | n/r |